CI Q1 2026 Earnings Call Summary

Cigna Group Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenues: $68.5 billion, representing a year-over-year increase.
Adjusted Earnings Per Share (EPS): $7.79, up 16% year-over-year.
After-tax Special Items Charges: $322 million, or $1.22 per share.
Medical Care Ratio (MCR): 79.8% for Cigna Healthcare, favorable compared to expectations due to lower flu volumes and weather-related care deferrals.
Earnings Growth: Cigna Healthcare's earnings grew 18% year-over-year.

2. Strategic Updates and Business Highlights

Leadership Transition: David Cordani will transition to Executive Chair on July 1, 2026, with Brian Evanko taking over as CEO.
Portfolio Shaping: Cigna announced plans to exit the individual exchange business by the end of 2026 and is exploring strategic alternatives for eviCore, aiming to focus on core growth platforms.
Evernorth Performance: Strong growth in Specialty and Care Services, with adjusted earnings up 20% to $1.1 billion. The Pharmacy Benefit Services (PBS) segment's earnings decreased by 28% due to large client renewals and investments in the new rebate-free model, [Signature].
Innovative Offerings: Introduction of the [Signature] pharmacy benefits model, aimed at enhancing affordability and transparency for consumers.

3. Forward Guidance and Outlook

Increased Full-Year 2026 Adjusted EPS Guidance: Raised to at least $30.35, reflecting confidence in sustained growth.
Earnings Expectations: Anticipated second-quarter adjusted EPS to be approximately 25% of the full-year outlook.
Evernorth's Full-Year Adjusted Income: Expected to be at least $6.9 billion.
Cigna Healthcare's Full-Year Pretax Adjusted Earnings: Expected to be at least $4.525 billion.

4. Bad News, Challenges, or Points of Concern

Declining Metrics in PBS: The PBS segment experienced a significant earnings decline, attributed to client renewals and investments in the new model.
Exit from Individual Exchange Business: This decision reflects challenges in scaling the business and maintaining management focus, which could impact revenue.
Market Pressures: Rising healthcare costs and the need for personalized care continue to challenge the industry, requiring ongoing innovation and adaptation.

5. Notable Q&A Insights

Client Transition to New PBM Model: Brian Evanko discussed the rollout of the [Signature] model, emphasizing that while it won't be fully operational until 2028, client interest is strong, with expectations for at least 50% adoption by year-end 2028.
Impact of Biosimilars: The company highlighted strong growth in biosimilar adoption, particularly with drugs like STELARA, which is expected to contribute positively to earnings.
340B Exposure: Cigna's strategy regarding 340B programs focuses on supporting hospitals rather than being a scaled contract pharmacy, which limits exposure but enhances service offerings.
GLP-1 Programs: The uptake of GLP-1 drugs is stable, with ongoing efforts to balance affordability for employers and satisfaction for employees. The introduction of oral versions is expected to improve affordability.

Overall, Cigna Group reported strong first-quarter results, raised its full-year guidance, and outlined strategic initiatives aimed at enhancing its core business while navigating industry challenges.

CI — Cigna Corporation